Evolution of hepatitis B management in kidney transplantation

World Journal of Gastroenterology

Volumn 20, Issue 2, 2014, Pages 468-474

  Yap, Desmond Y H ^a   Chan, Tak Mao ^a  

^a UNIVERSITY OF HONG KONG   (Hong Kong)

Author keywords

Hepatitis B; Kidney transplantation

Indexed keywords

ADEFOVIR; ALANINE AMINOTRANSFERASE; ENTECAVIR; LAMIVUDINE; TELBIVUDINE; TENOFOVIR; ANTIVIRUS AGENT; BIOLOGICAL MARKER; HEPATITIS B SURFACE ANTIGEN;

ANTIVIRAL ACTIVITY; ARTICLE; CHOLESTATIC HEPATITIS; CLINICAL TRIAL (TOPIC); DISEASE ASSOCIATION; HEPATITIS B; HUMAN; IMMUNOSUPPRESSIVE TREATMENT; KIDNEY TRANSPLANTATION; LIVER CANCER; LIVER CIRRHOSIS; META ANALYSIS (TOPIC); NEPHROTOXICITY; OUTCOME ASSESSMENT; RENAL GRAFT DYSFUNCTION; ANTIVIRAL RESISTANCE; BLOOD; DRUG EFFECTS; GRAFT SURVIVAL; HEPATITIS B, CHRONIC; MORTALITY; PATIENT SELECTION; RISK ASSESSMENT; RISK FACTOR; TRANSMISSION; TREATMENT OUTCOME;

ANTIVIRAL AGENTS; BIOLOGICAL MARKERS; DRUG RESISTANCE, VIRAL; GRAFT SURVIVAL; HEPATITIS B SURFACE ANTIGENS; HEPATITIS B, CHRONIC; HUMANS; KIDNEY TRANSPLANTATION; PATIENT SELECTION; RISK ASSESSMENT; RISK FACTORS; TREATMENT OUTCOME;

EID: 84892892578     PISSN: 10079327     EISSN: 22192840     Source Type: Journal    
DOI: 10.3748/wjg.v20.i2.468     Document Type: Article

References (57)

1. Chan TM, Fang GX, Tang CS, Cheng IK, Lai KN, Ho SK. Preemptive lamivudine therapy based on HBV DNA level in HBsAg-positive kidney allograft recipients. Hepatology 2002; 36: 1246-1252 [PMID: 12395336 DOI: 10.1053/ jhep.2002.36156]
2. Pirson Y, Alexandre GP, Ypersele C. Long-term effect of hbs antigenemia on patient survival after renal transplantation. N Engl J Med 1977; 296: 194-196 [PMID: 318729 DOI: 10.1056/ NEJM197701272960404]
3. Parfrey PS, Forbes RD, Hutchinson TA, Beaudoin JG, Dauphinee WD, Hollomby DJ, Guttmann RD. The clinical and pathological course of hepatitis B liver disease in renal transplant recipients. Transplantation 1984; 37: 461-466 [PMID: 6375001]
4. Harnett JD, Zeldis JB, Parfrey PS, Kennedy M, Sircar R, Steinmann TI, Guttmann RD. Hepatitis B disease in dialysis and transplant patients. Further epidemiologic and serologic studies. Transplantation 1987; 44: 369-376 [PMID: 2820093]
5. Rao KV, Kasiske BL, Anderson WR. Variability in the morphological spectrum and clinical outcome of chronic liver disease in hepatitis B-positive and B-negative renal transplant recipients. Transplantation 1991; 51: 391-396 [PMID: 1994533]
6. Bang BK, Yang CW, Yoon SA, Kim YS, Chang YS, Yoon YS, Koh YB. Prevalence and clinical course of hepatitis B and hepatitis C liver disease in ciclosporin-treated renal allograft recipients. Nephron 1995; 70: 397-401 [PMID: 7477642]
7. Parfrey PS, Forbes RD, Hutchinson TA, Kenick S, Farge D, Dauphinee WD, Seely JF, Guttmann RD. The impact of renal transplantation on the course of hepatitis B liver disease. Transplantation 1985; 39: 610-615 [PMID: 3890290]
8. Fornairon S, Pol S, Legendre C, Carnot F, Mamzer-Bruneel MF, Brechot C, Kreis H. The long-term virologic and pathologic impact of renal transplantation on chronic hepatitis B virus infection. Transplantation 1996; 62: 297-299 [PMID: 8755832]
9. Mathurin P, Mouquet C, Poynard T, Sylla C, Benalia H, Fretz C, Thibault V, Cadranel JF, Bernard B, Opolon P, Coriat P, Bitker MO. Impact of hepatitis B and C virus on kidney transplantation outcome. Hepatology 1999; 29: 257-263 [PMID: 9862875 DOI: 10.1002/hep.510290123]
10. Chan TM, Wu PC, Li FK, Lai CL, Cheng IK, Lai KN. Treatment of fibrosing cholestatic hepatitis with lamivudine. Gastroenterology 1998; 115: 177-181 [PMID: 9649474]
11. Oguchi H, Miyasaka M, Tokunaga S, Hora K, Ichikawa S, Ochi T, Yamada K, Nagasawa M, Kanno Y, Aizawa T. Hepatitis virus infection (HBV and HCV) in eleven Japanese hemodialysis units. Clin Nephrol 1992; 38: 36-43 [PMID: 1499167]
12. Su Y, Yan R, Duan Z, Norris JL, Wang L, Jiang Y, Xing W, Chen Y, Xiao Y, Li L, Tao J, Wang N. Prevalence and risk factors of hepatitis C and B virus infections in hemodialysis patients and their spouses: a multicenter study in Beijing, China. J Med Virol 2013; 85: 425-432 [PMID: 23341370 DOI: 10.1002/jmv.23486]
13. Finelli L, Miller JT, Tokars JI, Alter MJ, Arduino MJ. National surveillance of dialysis-associated diseases in the United States, 2002. Semin Dial 2005; 18: 52-61 [PMID: 15663766 DOI: 10.1111/j.1525-139X.2005.18108.x]
14. Te HS, Jensen DM. Epidemiology of hepatitis B and C viruses: a global overview. Clin Liver Dis 2010; 14: 1-21, vii [PMID: 20123436 DOI: 10.1016/j.cld.2009.11.009]
15. Han DJ, Kim TH, Park SK, Lee SK, Kim SB, Yang WS, Park JS, Jung JG, Yu ES, Kim SC. Results on preemptive or prophylactic treatment of lamivudine in HBsAg (+) renal allograft recipients: comparison with salvage treatment after hepatic dysfunction with HBV recurrence. Transplantation 2001; 71: 387-394 [PMID: 11233898]
16. DaRoza G, Loewen A, Djurdjev O, Love J, Kempston C, Burnett S, Kiaii M, Taylor PA, Levin A. Stage of chronic kidney disease predicts seroconversion after hepatitis B immunization: earlier is better. Am J Kidney Dis 2003; 42: 1184-1192 [PMID: 14655190 DOI: 10.1053/j.ajkd.2003.08.019]
17. Rangel MC, Coronado VG, Euler GL, Strikas RA. Vaccine recommendations for patients on chronic dialysis. The Advisory Committee on Immunization Practices and the American Academy of Pediatrics. Semin Dial 2000; 13: 101-107 [PMID: 10795113 DOI: 10.1046/j.1525-139x.2000.00029.x]
18. Choy BY, Peiris JS, Chan TM, Lo SK, Lui SL, Lai KN. Immunogenicity of intradermal hepatitis B vaccination in renal transplant recipients. Am J Transplant 2002; 2: 965-969 [PMID: 12482150 DOI: 10.1034/j.1600-6143.2002.21014.x]
19. Wolf JL, Perkins HA, Schreeder MT, Vincenti F. The transplanted kidney as a source of hepatitis B infection. Ann Intern Med 1979; 91: 412-413 [PMID: 382937 DOI: 10.7326/00 03-4819-91-3-412]
20. Wachs ME, Amend WJ, Ascher NL, Bretan PN, Emond J, Lake JR, Melzer JS, Roberts JP, Tomlanovich SJ, Vincenti F. The risk of transmission of hepatitis B from HBsAg(-), HBcAb(+), HBIgM(-) organ donors. Transplantation 1995; 59: 230-234 [PMID: 7839446]
21. Jiang H, Wu J, Zhang X, Wu D, Huang H, He Q, Wang R, Wang Y, Zhang J, Chen J. Kidney transplantation from hepatitis B surface antigen positive donors into hepatitis B surface antibody positive recipients: a prospective nonrandomized controlled study from a single center. Am J Transplant 2009; 9: 1853-1858 [PMID: 19538486 DOI: 10.1111/ j.1600-6143.2009.02707.x]
22. Fabrizi F, Martin P, Dixit V, Kanwal F, Dulai G. HBsAg seropositive status and survival after renal transplantation: meta-analysis of observational studies. Am J Transplant 2005; 5: 2913-2921 [PMID: 16303005 DOI: 10.1111/ j.1600-6143.2005.01113.x]
23. Fairley CK, Mijch A, Gust ID, Nichilson S, Dimitrakakis M, Lucas CR. The increased risk of fatal liver disease in renal transplant patients who are hepatitis Be antigen and/or HBV DNA positive. Transplantation 1991; 52: 497-500 [PMID: 1897022]
24. Yap DY, Tang CS, Yung S, Choy BY, Yuen MF, Chan TM. Long-term outcome of renal transplant recipients with chronic hepatitis B infection-impact of antiviral treatments. Transplantation 2010; 90: 325-330 [PMID: 20562676 DOI: 10.1097/TP.0b013e3181e5b811]
25. Sonneveld MJ, Janssen HL. Pros and Cons of Peginterferon Versus Nucleos(t)ide Analogues for Treatment of Chronic Hepatitis B. Curr Hepat Rep 2010; 9: 91-98 [PMID: 20461129 DOI: 10.1007/s11901-010-0041-7]
26. Yuen MF, Hui CK, Cheng CC, Wu CH, Lai YP, Lai CL. Long-term follow-up of interferon alfa treatment in Chinese patients with chronic hepatitis B infection: The effect on hepatitis B e antigen seroconversion and the development of cirrhosis-related complications. Hepatology 2001; 34: 139-145 [PMID: 11431745 DOI: 10.1053/jhep.2001.25273]
27. Marcellin P, Bonino F, Lau GK, Farci P, Yurdaydin C, Piratvisuth T, Jin R, Gurel S, Lu ZM, Wu J, Popescu M, Hadziyannis S. Sustained response of hepatitis B e antigen-negative patients 3 years after treatment with peginterferon alpha-2a. Gastroenterology 2009; 136: 2169-2179. e1-4 [PMID: 19303414 DOI: 10.1053/j.gastro.2009.03.006]
28. Rostaing L, Modesto A, Baron E, Cisterne JM, Chabannier MH, Durand D. Acute renal failure in kidney transplant patients treated with interferon alpha 2b for chronic hepatitis C. Nephron 1996; 74: 512-516 [PMID: 8938673]
29. Durlik M, Gaciong Z, Rowińska D, Rancewicz Z, Lewandowska D, Kozłowska B, Wyzgał J, Soluch L, Walewska-Zielecka B, Rowiński W, Lao M. Long-term results of treatment of chronic hepatitis B, C and D with interferon-alpha in renal allograft recipients. Transpl Int 1998; 11 Suppl 1: S135-S139 [PMID: 9664963 DOI: 10.1111/j.1432-2277.1998. tb01097.x]
30. Sanai FM, Mousa D, Al-Mdani A, Al-Shoail G, Al-Ashgar H, Al Meshari K, Al-Qahtani A, Saadeh M, Bzeizi KI, Aleid H. Safety and efficacy of peginterferon-α2a plus ribavirin treatment in renal transplant recipients with chronic hepatitis C. J Hepatol 2013; 58: 1096-1103 [PMID: 23428875 DOI: 10.1016/ j.jhep.2013.02.004]
31. Filik L, Karakayali H, Moray G, Dalgiç A, Emiroǧlu R, Ozdemir N, Colak T, Gür G, Yilmaz U, Haberal M. Lamivudine therapy in kidney allograft recipients who are seropositive for hepatitis B surface antigen. Transplant Proc 2006; 38: 496-498 [PMID: 16549158 DOI: 10.1016/j.transproce ed.2005.12.047]
32. Rostaing L, Henry S, Cisterne JM, Duffaut M, Icart J, Durand D. Efficacy and safety of lamivudine on replication of recurrent hepatitis B after cadaveric renal transplantation. Transplantation 1997; 64: 1624-1627 [PMID: 9415572]
33. Fabrizi F, Dulai G, Dixit V, Bunnapradist S, Martin P. Lamivudine for the treatment of hepatitis B virus-related liver disease after renal transplantation: meta-analysis of clinical trials. Transplantation 2004; 77: 859-864 [PMID: 15077027 DOI: 10.1097/01.TP.0000116448.97841.6D]
34. Thabut D, Thibault V, Bernard-Chabert B, Mouquet C, Di Martino V, Le Calvez S, Opolon P, Benhamou Y, Bitker MO, Poynard T. Long-term therapy with lamivudine in renal transplant recipients with chronic hepatitis B. Eur J Gastroenterol Hepatol 2004; 16: 1367-1373 [PMID: 15618847]
35. Chan TM, Tse KC, Tang CS, Lai KN, Ho SK. Prospective study on lamivudine-resistant hepatitis B in renal allograft recipients. Am J Transplant 2004; 4: 1103-1109 [PMID: 15196068 DOI: 10.1111/j.1600-6143.2004.00467.x]
36. Hadziyannis SJ, Tassopoulos NC, Heathcote EJ, Chang TT, Kitis G, Rizzetto M, Marcellin P, Lim SG, Goodman Z, Ma J, Brosgart CL, Borroto-Esoda K, Arterburn S, Chuck SL. Long-term therapy with adefovir dipivoxil for HBeAgnegative chronic hepatitis B for up to 5 years. Gastroenterology 2006; 131: 1743-1751 [PMID: 17087951 DOI: 10.1053/ j.gastro.2006.09.020]
37. Fontaine H, Vallet-Pichard A, Chaix ML, Currie G, Serpaggi J, Verkarre V, Varaut A, Morales E, Nalpas B, Brosgart C, Pol S. Efficacy and safety of adefovir dipivoxil in kidney recipients, hemodialysis patients, and patients with renal insufficiency. Transplantation 2005; 80: 1086-1092 [PMID: 16278590 DOI: 10.1097/01.tp.0000178305.39231.a2]
38. Garcia A, Mazuecos A, González P, Diaz F, Garcia T, Ceballos M, Rivero M. Treatment with adefovir dipivoxil in a renal transplant patient with renal insufficiency and lamivudine-resistant hepatitis B infection. Transplant Proc 2005; 37: 1462-1463 [PMID: 15866639 DOI: 10.1016/j.transproceed.200 5.02.010]
39. de Silva HJ, Dassanayake AS, Manamperi A, de Silva AP. Treatment of lamivudine-resistant hepatitis B infection in post-renal transplant patients with adefovir dipivoxil: preliminary results. Transplant Proc 2006; 38: 3118-3120 [PMID: 17112914 DOI: 10.1016/j.transproceed.2006.08.186]
40. Kamar N, Huart A, Tack I, Alric L, Izopet J, Rostaing L. Renal side effects of adefovir in hepatitis B virus-(HBV) positive kidney allograft recipients. Clin Nephrol 2009; 71: 36-42 [PMID: 19203548]
41. Lampertico P, Viganò M, Facchetti F, Invernizzi F, Aroldi A, Lunghi G, Messa PG, Colombo M. Long-term add-on therapy with adefovir in lamivudine-resistant kidney graft recipients with chronic hepatitis B. Nephrol Dial Transplant 2011; 26: 2037-2041 [PMID: 21486869 DOI: 10.1093/ndt/gfr174]
42. Lai HW, Chang CC, Chen TH, Tsai MC, Chen TY, Lin CC. Safety and efficacy of adefovir therapy for lamivudine-resistant hepatitis B virus infection in renal transplant recipients. J Formos Med Assoc 2012; 111: 439-444 [PMID: 22939662 DOI: 10.1016/j.jfma.2011.05.010]
43. Tse KC, Yap DY, Tang CS, Yung S, Chan TM. Response to adefovir or entecavir in renal allograft recipients with hepatitic flare due to lamivudine-resistant hepatitis B. Clin Transplant 2010; 24: 207-212 [PMID: 19758269 DOI: 10.1111/ j.1399-0012.2009.01090.x]
44. Yuen MF, Seto WK, Fung J, Wong DK, Yuen JC, Lai CL. Three years of continuous entecavir therapy in treatmentnaïve chronic hepatitis B patients: VIRAL suppression, viral resistance, and clinical safety. Am J Gastroenterol 2011; 106: 1264-1271 [PMID: 21364549 DOI: 10.1038/ajg.2011.45]
45. Lok AS, McMahon BJ. Chronic hepatitis B. Hepatology 2007; 45: 507-539 [PMID: 17256718 DOI: 10.1002/hep.21513]
46. Tenney DJ, Rose RE, Baldick CJ, Pokornowski KA, Eggers BJ, Fang J, Wichroski MJ, Xu D, Yang J, Wilber RB, Colonno RJ. Long-term monitoring shows hepatitis B virus resistance to entecavir in nucleoside-naïve patients is rare through 5 years of therapy. Hepatology 2009; 49: 1503-1514 [PMID: 19280622 DOI: 10.1002/hep.22841]
47. Hu TH, Tsai MC, Chien YS, Chen YT, Chen TC, Lin MT, Chang KC, Chiu KW. A novel experience of antiviral therapy for chronic hepatitis B in renal transplant recipients. Antivir Ther 2012; 17: 745-753 [PMID: 22522918 DOI: 10.3851/ IMP2097]
48. Kamar N, Milioto O, Alric L, El Kahwaji L, Cointault O, Lavayssière L, Sauné K, Izopet J, Rostaing L. Entecavir therapy for adefovir-resistant hepatitis B virus infection in kidney and liver allograft recipients. Transplantation 2008; 86: 611-614 [PMID: 18724232 DOI: 10.1097/TP.0b013e3181806c8c]
49. Yim HJ, Seo YS, Yoon EL, Kim CW, Lee CD, Park SH, Lee MS, Park CK, Chae HB, Kim MY, Baik SK, Kim YS, Kim JH, Lee JI, Lee JW, Hong SP, Um SH. Adding adefovir vs. switching to entecavir for lamivudine-resistant chronic hepatitis B (ACE study): a 2-year follow-up randomized controlled trial. Liver Int 2013; 33: 244-254 [PMID: 23295056 DOI: 10.1111/liv.12036]
50. Jenh AM, Thio CL, Pham PA. Tenofovir for the treatment of hepatitis B virus. Pharmacotherapy 2009; 29: 1212-1227 [PMID: 19792994 DOI: 10.1592/phco.29.10.1212]
51. Krummel T, Parvez-Braun L, Frantzen L, Lalanne H, Marcellin L, Hannedouche T, Moulin B. Tenofovir-induced acute renal failure in an HIV patient with normal renal function. Nephrol Dial Transplant 2005; 20: 473-474 [PMID: 15673708 DOI: 10.1093/ndt/gfh640]
52. Daudé M, Rostaing L, Sauné K, Lavayssière L, Basse G, Esposito L, Guitard J, Izopet J, Alric L, Kamar N. Tenofovir therapy in hepatitis B virus-positive solid-organ transplant recipients. Transplantation 2011; 91: 916-920 [PMID: 21325995 DOI: 10.1097/TP.0b013e3182100f59]
53. Lai CL, Gane E, Liaw YF, Hsu CW, Thongsawat S, Wang Y, Chen Y, Heathcote EJ, Rasenack J, Bzowej N, Naoumov NV, Di Bisceglie AM, Zeuzem S, Moon YM, Goodman Z, Chao G, Constance BF, Brown NA. Telbivudine versus lamivudine in patients with chronic hepatitis B. N Engl J Med 2007; 357: 2576-2588 [PMID: 18094378 DOI: 10.1056/NEJMoa066422]
54. Gane EJ, Wang Y, Liaw YF, Hou J, Thongsawat S, Wan M, Moon YM, Jia J, Chao YC, Niu J, Leung N, Samuel D, Hsu CW, Bao W, Lopez P, Avila C. Efficacy and safety of prolonged 3-year telbivudine treatment in patients with chronic hepatitis B. Liver Int 2011; 31: 676-684 [PMID: 21457439 DOI: 10.1111/j.1478-3231.2011.02490.x]
55. Sangiovanni A, Del Ninno E, Fasani P, De Fazio C, Ronchi G, Romeo R, Morabito A, De Franchis R, Colombo M. Increased survival of cirrhotic patients with a hepatocellular carcinoma detected during surveillance. Gastroenterology 2004; 126: 1005-1014 [PMID: 15057740 DOI: 10.1053/ j.gastro.2003.12.049]
56. Zoli M, Magalotti D, Bianchi G, Gueli C, Marchesini G, Pisi E. Efficacy of a surveillance program for early detection of hepatocellular carcinoma. Cancer 1996; 78: 977-985 [PMID: 8780534]
57. Poon RT, Fan ST, Ng IO, Lo CM, Liu CL, Wong J. Different risk factors and prognosis for early and late intrahepatic recurrence after resection of hepatocellular carcinoma. Cancer 2000; 89: 500-507 [PMID: 10931448]